HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.
HIV/HCV coinfected people who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured -- with outcomes worsening the longer it is put off -- indicating that treatment should not be deferred until advanced disease, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Treating only after progression to cirrhosis increased the risk of liver-related death by more than 5-fold and the duration of infectiousness by 4-fold.
The UK PROUD study of once-daily Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP), and the French Ipergay study of "on-demand" PrEP taken before and after sex, both saw an 86% reduction in new HIV infections, researchers reported at the at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle.
Research towards a cure for HIV continues, despite some recent setbacks. Several investigators presented their work in a session on HIV persistence, latency reversal, and viremia rebound at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle. There is still enthusiasm in the HIV cure field, said John Mellors of the University of Pittsburgh, but progress will be slow.